Christopher MacLeod, a director at Zomedica Corp., has reported a substantial stock appreciation right transaction involving 1,823,107 shares. This move, filed on November 17, 2026, is significant as it indicates MacLeod's confidence in the company's future performance and aligns his interests with those of shareholders.

Zomedica Corp. operates in the pharmaceutical preparations sector, focusing on developing innovative solutions for animal health. The company is headquartered in Ann Arbor, Michigan, and is listed under the ticker symbol ZOMDF. This recent filing is part of a series of disclosures made by MacLeod, with the last one prior to this being on November 18, 2025.

The filing details that the stock appreciation right was exercised on November 16, 2026, at a conversion price of $0.10 per share. The transaction was coded as an acquisition, and following this transaction, MacLeod retains ownership of 1,823,107 shares. The expiration date for this right is set for November 15, 2036, providing a long-term incentive for MacLeod to continue contributing to the company’s success.

This transaction may affect various stakeholders, including Zomedica's shareholders and employees, as it demonstrates the leadership's commitment to enhancing shareholder value. The pharmaceutical preparations industry, in general, may witness similar actions as executives look to align their compensation with company performance.

The filing does not say what happens next, but it underscores the ongoing commitment of Zomedica's leadership to drive growth and innovation in the animal health sector.